Antipsychotic use in dementia: is there a problem and are there solutions?

J Kirkham, C Sherman, C Velkers… - The Canadian …, 2017 - journals.sagepub.com
Antipsychotics are necessary for many older adults to treat major mental illnesses or reduce
distressing psychiatric symptoms. Current controversy exists over the role of antipsychotics …

[HTML][HTML] The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand?

G Trifirò, R Gini, F Barone-Adesi, E Beghi, A Cantarutti… - Drug Safety, 2019 - Springer
Enormous progress has been made globally in the use of evidence derived from patients'
clinical information as they access their routine medical care. The value of real-world data …

[PDF][PDF] The use of antipsychotic medication for people with dementia: Time for action

S Banerjee - 2009 - psychrights.org
Examining the literature, there is a clear emerging consensus about the positive and
negative effects of antipsychotic drugs. This review has benefited from being able to access …

[PDF][PDF] Using the R-MAPE index as a resistant measure of forecast accuracy

JJM Moreno, AP Pol, AS Abad, BC Blasco - Psicothema, 2013 - redalyc.org
Background: The mean absolute percentage error (MAPE) is probably the most widely used
goodness-of-fi t measure. However, it does not meet the validity criterion due to the fact that …

Impact of FDA black box advisory on antipsychotic medication use

ER Dorsey, A Rabbani, SA Gallagher… - Archives of internal …, 2010 - jamanetwork.com
Background In April 2005, the US Food and Drug Administration (FDA) issued an advisory
and subsequent black box warning regarding the risks of atypical anti psychotic use among …

Trends in antipsychotic use in dementia 1999-2007

HC Kales, K Zivin, HM Kim, M Valenstein… - Archives of general …, 2011 - jamanetwork.com
Context Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased
markedly in the 1990s. Concerns about their use began to emerge in 2002, and in 2005, the …

Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)

E Poluzzi, E Raschi, U Moretti… - … and drug safety, 2009 - Wiley Online Library
Aims To investigate spontaneous reports of TdP present in the public version of the FDA
Adverse Event Reporting System (AERS) in the light of what is already known on their TdP …

Nonpharmacological management of behavioral and psychological symptoms of dementia: what works, in what circumstances, and why?

S Caspar, ED Davis, A Douziech, DR Scott - Innovation in Aging, 2017 - academic.oup.com
Objective Behavioral and psychological symptoms of dementia (BPSD) refer to the often
distressing, noncognitive symptoms of dementia. BPSD appear in up to 90% of persons with …

Measuring the impact of medicines regulatory interventions–systematic review and methodological considerations

T Goedecke, DR Morales, A Pacurariu… - British Journal of …, 2018 - Wiley Online Library
Aims Evaluating the public health impact of regulatory interventions is important but there is
currently no common methodological approach to guide this evaluation. This systematic …

Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings

A Gallini, S Andrieu, JM Donohue, N Oumouhou… - European …, 2014 - Elsevier
Based on evidence of an increased risk of death, drug agencies issued safety warnings
about the use of second generation antipsychotics (SGAs) in the elderly with dementia. The …